h1

h2

h3

h4

h5
h6
% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@PHDTHESIS{Zhu:63710,
      author       = {Zhu, Leilei},
      othercontributors = {Schwaneberg, Ulrich},
      title        = {{D}irected evolution of arginine deiminase ({ADI}) for
                      anti-tumor application},
      address      = {Aachen},
      publisher    = {Publikationsserver der RWTH Aachen University},
      reportid     = {RWTH-CONV-125135},
      pages        = {IX, 98 : Ill., graph. Darst.},
      year         = {2010},
      note         = {Aachen, Techn. Hochsch., Diss., 2010},
      abstract     = {Arginine deiminase (ADI), an arginine-degrading enzyme, is
                      involved in the first step of arginine dihydrolase pathway.
                      It catalyzes the hydrolysis of L-arginine to form citrulline
                      and ammonia. ADI has been studied as a potential cancer
                      therapeutic agent for the arginine-auxotrophic tumors, such
                      as hepatocellular carcinomas (HCC) and melanomas.
                      Furthermore, studies also indicate that ADI is a potential
                      anti-angiogenic agent; therefore it could become a novel
                      anti-cancer drug targeting the neovascularization-related
                      tumors. Studies show ADI is more potent for the treatment of
                      leukemia than L-asparaginase. However, the anti-tumor
                      application of ADI for therapeutic purpose faces
                      considerable challenges, such as, microbial ADI has low
                      activity at physiological pH (7.35~7.45), short circulating
                      half-life (~5 h) and high antigenicity. Pegylation of ADI
                      improved its efficacy as a clinical drug, including its
                      half-life in serum and antigenicity. The aim of the project
                      is to improve ADI catalytic performance at physiological pH
                      by directed evolution. Protein engineering by rational
                      design and directed evolution offers opportunities to tailor
                      ADI properties to physiological conditions. Directed protein
                      evolution has over the last decades become a versatile and
                      successful approach for tailoring protein properties to
                      industrial demands and for advancing our understanding of
                      structure-function relationships in biocatalysts. Unlike
                      rational design relying on the gathering of extensive
                      structure-function relationships of enzymes, directed
                      evolution is used to reengineer enzyme properties through
                      iterative rounds of diversity generation and function
                      selection for improved variants. In order to improve the ADI
                      activity at physiological pH, we established a directed
                      evolution protocol for this purpose. A microtiter plate
                      (MTP) format colorimetric screening assay based on
                      citrulline detection with diacetyl monoxime (DAM) was
                      developed. Reaction temperature for color development and
                      DAM concentration were optimized to ensure sufficient
                      sensitivity, appropriate linear range and throughput. With
                      the optimized assay and PpADI wild type expressed in E. coli
                      as a model protein, true standard deviation $12.8\%$ was
                      obtained, which is appropriate for the library screening.
                      With the established microtiter plate assay system, for the
                      first time, we reengineered ADI for improved activity at
                      physiological pH (pH 7.4) with higher potency in medical
                      application. After one site directed mutagenesis and one
                      round of epPCR library screening, variant M2
                      (K5T/D44E/H404R) was obtained. M2 shows 4-fold improved kcat
                      value than the PpADI wild type, a shifted pH optimum at pH
                      7.0 (by 0.5 pH unit), and however an increased Km value,
                      3.6-fold under assay conditions (0.5 M sodium phosphate
                      buffer). Low Km (S0.5) value for ADI is an important factor
                      for efficient consume of arginine in plasma because of the
                      low arginine concentration in human plasma (100-120 µM).
                      Therefore after our proof of concept of reengineering PpADI
                      by directed evolution, we aim to decrease the Km value of
                      PpADI towards arginine and improve the kcat furthermore
                      thereby improve the efficiency of arginine depletion by ADI.
                      The established citrulline colorimetric assay in 96-well
                      microtiter plate is improved to reflect application
                      conditions: PBS buffer and 1 mM arginine were used in
                      screening system. After the second round of epPCR library
                      and site directed mutagenesis, variant M5
                      (K5T/D38H/D44E/A128T/H404R) and M6
                      (K5T/D38H/D44E/A128T/E296K/H404R) were generated: at pH 7.4
                      (PBS buffer), the S0.5 value decrease from 2.01 mM (parent
                      M3, K5T/D44E/A128T/H404R) to 1.48 mM (M5) and 0.81 mM (M6).
                      Under physiological pH in PBS buffer, the S0.5 value of M6
                      (0.81 mM) is lower than that of PpADI wild type (1.30 mM);
                      the kcat value improved from 0.18 s-1 (PpADI wild type) to
                      17.56 s-1 (M5, 97.6-folds) and 11.64 s-1 (M6, 64.7-fold).},
      keywords     = {Gerichtete Evolution (SWD)},
      cin          = {162610 / 160000},
      ddc          = {570},
      cid          = {$I:(DE-82)162610_20140620$ / $I:(DE-82)160000_20140620$},
      shelfmark    = {WF 9720},
      typ          = {PUB:(DE-HGF)11},
      urn          = {urn:nbn:de:hbz:82-opus-33679},
      url          = {https://publications.rwth-aachen.de/record/63710},
}